Production (Stage)
AEON Biopharma, Inc.
AEON
$0.84
-$0.02-2.33%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.13M | 2.63M | 3.04M | 3.32M | 4.65M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.95M | 5.67M | 4.02M | 7.76M | 10.38M |
| Operating Income | -3.95M | -5.67M | -4.02M | -7.76M | -10.38M |
| Income Before Tax | 9.10M | 2.08M | -6.17M | 164.11M | -118.02M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 9.10M | 2.08M | -6.17M | 164.11M | -118.02M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.10M | 2.08M | -6.17M | 164.11M | -118.02M |
| EBIT | -3.95M | -5.67M | -4.02M | -7.76M | -10.38M |
| EBITDA | -3.93M | -5.64M | -3.99M | -7.74M | -10.36M |
| EPS Basic | 2.28 | 3.76 | -11.24 | 304.20 | -227.87 |
| Normalized Basic EPS | 1.14 | -5.35 | -4.89 | 1.26 | -65.36 |
| EPS Diluted | 2.28 | 3.47 | -11.52 | 304.20 | -227.87 |
| Normalized Diluted EPS | 1.14 | -5.34 | -4.89 | 1.26 | -65.36 |
| Average Basic Shares Outstanding | 3.98M | 554.30K | 548.80K | 539.50K | 517.90K |
| Average Diluted Shares Outstanding | 3.98M | 555.30K | 548.80K | 539.50K | 517.90K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |